RNA splicing, cell signaling, and response to therapies.

摘要: Purpose of review PremRNA alternative splicing is more a rule than an exception as it affects 90% multiexons genes and plays key role in proteome diversity. Here, we discuss some recent studies published the extensively growing field linking RNA cancer. Recent findings These last years, development high-throughput together with appropriate bioinformatic tools have led to identification new cancer-specific patterns that allow distinguish various cancer types, provide prognosis biomarkers. In addition, functional consequences hot spot mutations affecting components spliceosome machinery cancers been described. As example, missplicing enhancer zeste homolog 2 histone methyltransferase premRNA response mutation factor SRSF2 was found participate pathogenesis myelodysplastic syndrome. Moreover, proofs principle targeting can be used correct aberrant missplicing, kill oncogene-driven cells, or reverse resistance tumor cells targeted therapies done. another core spliceosomal function recently critical for survival Myc-driven breast rendering them hypersensitive inhibitors. Summary Dysregulation appears one hallmarks The characterization novel signatures well original signaling networks involving regulators should decipher oncogenic mechanisms develop therapeutic strategies.